CN103599525A - Chelated calcium electuary - Google Patents
Chelated calcium electuary Download PDFInfo
- Publication number
- CN103599525A CN103599525A CN201310551948.1A CN201310551948A CN103599525A CN 103599525 A CN103599525 A CN 103599525A CN 201310551948 A CN201310551948 A CN 201310551948A CN 103599525 A CN103599525 A CN 103599525A
- Authority
- CN
- China
- Prior art keywords
- osteoporosis
- chelated calcium
- electuary
- bone
- calcium electuary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a chelated calcium electuary, which is mainly prepared from L-asparaginic acid chelated calcium, casein phosphopeptide and vitamin D.
Description
Technical field
The invention belongs to biomedicine field, be specifically related to a kind of chelating calcium electuary.
Background technology
Osteoporosis is a kind of commonly encountered diseases and frequently-occurring disease, and it is seriously threatening middle-aged and elderly people, and especially postmenopausal women is healthy.The complication such as the fracture being caused by osteoporosis, have caused great misery to patient, return society and family and have brought heavy economy and living burden.According to reports, the probability that the osteoporotic women of generation occurred hip, spinal column, forearm or proximal humeral fracture in 10 years later in 50 years old is up to 45%; Be greater than 65 years old old man when unconscious falling, have 87% can cause osteoporotic fracture.China old people's absolute quantity accounts for No. 1 in the world, and along with the growth of growth in the living standard and population life, the aged sharply increases, and therefore, the diagnosis of osteoporosis and control thereof just seem very important.
Osteoporosis can be divided into three major types, and a class is primary osteoporosis, is a kind of physiological degeneration that must occur with advancing age.Equations of The Second Kind is secondary osteoporosis, and it is the osteoporosis of being brought out by some factors such as Other diseases or medicines.The 3rd class is idiopathic osteoporosis disease, is more common in teenager or the adult of 8～14 years old, mostly has family's heredity medical history, and women is more than male.The osteoporosis that gravid woman and women breast-feeding their children occur also can be listed idiopathic osteoporosis in, to cause people's attention.
The main clinical manifestation of osteoporosis and sign are: pain, height shortening, hunchback, fragility fractures and Respiratory Disturbances etc.
1) pain
Pain is the common sympton of osteoporosis, and its reason is mainly that bone resorption increases because bone conversion is high.In bone resorption process, bone trabecular destruction, disappearance, the destruction of subperiosteum cortical bone etc. all can cause general osteodynia, wherein common with lumbago and backache.Another causes that the major reason of pain is fracture.
2) height shortening, hunchback
In silent middle height, shortening or bow-backed, is one of important clinical sign occurring continue lumbago and backache after, and 5-20 centimetre of height shortening is not sometimes etc.
3) fragility fractures
In osteoporosis, skeleton fracture threshold reduces significantly, thereby just easily fractured by slight external force.
4) Respiratory Disturbances
Breast, compression fracture of lumbar vertebra due to serious osteoporosis, usually cause kyphosis, chest deformity, and thoracic cavity capacity obviously declines, and sometimes can cause the changes of function of a plurality of internal organs, and wherein the performance of respiratory system is particularly outstanding.
The final purpose of protect against osteoporosis is to reduce the generation of fracture.Adopt clinically and delay and reduce bone loss, strive for recapturing bone amount, increase bone strength and reach this object.The treatment measure of osteoporosis is divided into basic measure and two aspects of Drug therapy.In the measure of basis, bone health supplement are mainly calcium preparation and vitamin D; Drug therapy mainly comprises anti-bone resorption medicine, short bone formation medicine and other drug.
Summary of the invention
The object of the present invention is to provide a kind of chelating calcium electuary.
For achieving the above object, the present invention adopts the component of following weight ratio: 20 parts of ASPARTIC ACID chelating calcium, 5 parts of phosphopeptide caseinates, 0.05 part of vitamin D.
The above-mentioned edible or pharmaceutic adjuvant that can add comprises: diluent, suspending agent, antioxidant, emulsifying agent, disintegrating agent, adhesive and antiseptic.
The specific embodiment
Embodiment 1: chelating calcium electuary, its raw material and weight portion are: 20 parts of ASPARTIC ACID chelating calcium, 5 parts of phosphopeptide caseinates, 0.05 part of vitamin D.
Claims (1)
1. chelating calcium electuary, is characterized in that, comprises the component of following weight ratio: 20 parts of ASPARTIC ACID chelating calcium, 5 parts of phosphopeptide caseinates, 0.05 part of vitamin D.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310551948.1A CN103599525A (en) | 2013-11-08 | 2013-11-08 | Chelated calcium electuary |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310551948.1A CN103599525A (en) | 2013-11-08 | 2013-11-08 | Chelated calcium electuary |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103599525A true CN103599525A (en) | 2014-02-26 |
Family
ID=50117831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310551948.1A Pending CN103599525A (en) | 2013-11-08 | 2013-11-08 | Chelated calcium electuary |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103599525A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1310024A (en) * | 2001-02-21 | 2001-08-29 | 深圳市海川实业股份有限公司 | Microencapsulated compound nutrient complementing agent |
| CN102302116A (en) * | 2011-06-10 | 2012-01-04 | 营养屋(成都)生物医药有限公司 | Calcium supplementing and calcium locking health care food and preparation method thereof |
| CN102318835A (en) * | 2011-08-31 | 2012-01-18 | 石家庄中硕药业集团有限公司 | Composition for reducing bone loss and preparation method thereof |
| CN103169092A (en) * | 2013-03-21 | 2013-06-26 | 翁国富 | L-asparaginic acid chelated calcium drinking water |
-
2013
- 2013-11-08 CN CN201310551948.1A patent/CN103599525A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1310024A (en) * | 2001-02-21 | 2001-08-29 | 深圳市海川实业股份有限公司 | Microencapsulated compound nutrient complementing agent |
| CN102302116A (en) * | 2011-06-10 | 2012-01-04 | 营养屋(成都)生物医药有限公司 | Calcium supplementing and calcium locking health care food and preparation method thereof |
| CN102318835A (en) * | 2011-08-31 | 2012-01-18 | 石家庄中硕药业集团有限公司 | Composition for reducing bone loss and preparation method thereof |
| CN103169092A (en) * | 2013-03-21 | 2013-06-26 | 翁国富 | L-asparaginic acid chelated calcium drinking water |
Non-Patent Citations (1)
| Title |
|---|
| 国家食品药品监督管理总局: "给尔新冲剂（L-天门冬氨酸钙）", 《国家食品药品监督管理总局数据库》, 9 October 1999 (1999-10-09) * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103584106A (en) | Composition capable of improving bone mineral density | |
| CN103599186A (en) | Compound lotus root starch preparation | |
| CN103610755A (en) | Granules for treating osteoporosis | |
| CN104587470B (en) | Pharmaceutical composition for promoting bone healing after osteoportic fracture operations and application of pharmaceutical composition | |
| CN103565827A (en) | Resveratrol-containing tablets | |
| Chen et al. | Intrathoracic dislocation of the humeral head accompanied by polytrauma: How to treat it | |
| CN103599525A (en) | Chelated calcium electuary | |
| Oliver et al. | Hip fracture | |
| CN103599521A (en) | Vitamin D complex granules | |
| CN103611152A (en) | Compound vitamin D electuary | |
| CN103565830A (en) | Composite calcium preparation | |
| CN103599524A (en) | Compound walnut powder solid preparation | |
| CN103599096A (en) | Resveratrol tablet | |
| CN103610740A (en) | Calcium chelate | |
| CN103599168A (en) | Composition for enhancing bone density | |
| CN103599177A (en) | Composition for enhancing bone density | |
| CN103599174A (en) | Composition for improving bone mineral density | |
| CN103566355A (en) | Composite lotus root starch preparation | |
| CN103585457B (en) | A kind of medicament for the treatment of fracture | |
| CN103599176A (en) | Composition for enhancing bone density | |
| CN103585264A (en) | Preparation capable of increasing bone mineral density | |
| CN103735613A (en) | Preparation for increasing bone mineral density | |
| CN103623048A (en) | Preparation containing pueraria isoflavones | |
| CN103565930A (en) | Granule for increasing bone density | |
| CN103599175A (en) | Granules for increasing bone density |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C05 | Deemed withdrawal (patent law before 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140226 |